901730-21-0
Chemical Structure
TACR1-IN-1
- CAS No.: 901730-21-0
- Formula:C23H24FN3O3
- Molecular Weight:409.45
InChIKey: TYDFSQYEDVHERH-UHFFFAOYSA-N
SMILES: FC1=CC=C(N2CCN(C(COC3=CC(N(CC)C4=CC=CC=C43)=O)=O)CC2)C=C1
Biological Activity: TACR1-IN-1 is a TACR1 inhibitor. TACR1-IN-1 attenuates Substance P-driven ERK phosphorylation and downstream malignant programs. TACR1-IN-1 reduces PGP9.5-positive tumor innervation in orthotopic PDAC models. TACR1-IN-1 increases antigen presentation and immune chemokine-related transcript expression under Substance P treatment conditions. TACR1-IN-1 reverses Substance P-associated reduction in Gemcitabine (HY-17026) sensitivity. TACR1-IN-1 can be used for research on pancreatic ductal adenocarcinoma[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
TACR1-IN-1 | TACR1-IN-1 is a TACR1 inhibitor. TACR1-IN-1 attenuates Substance P-driven ERK phosphorylation and downstream malignant programs. TACR1-IN-1 reduces PGP9.5-positive tumor innervation in orthotopic PDAC models. TACR1-IN-1 increases antigen presentation and immune chemokine-related transcript expression under Substance P treatment conditions. TACR1-IN-1 reverses Substance P-associated reduction in Gemcitabine (HY-17026) sensitivity. TACR1-IN-1 can be used for research on pancreatic ductal adenocarcinoma. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
